II. Mechanism

  1. Bind directly to reverse transcriptase
  2. Prevents RNA conversion to DNA
  3. Completely different Mechanism than nRTI

III. Preparations: First Generation

  1. Delavirdine (Rescriptor)
  2. Efavirenz (Sustiva, EFV)
  3. Nevirapine (Viramune, NVP)

IV. Preparations: Second Generation

  1. Etravirine (Intelence)
    1. Approved in treatment experienced patients
  2. Rilpivirine (Endurant)
    1. FDA approved in 2011 for treatment-naive patients

V. Adverse Reaction

  1. See specific agents
  2. Hyperlipidemia
  3. Rash is common (especially with Nevirapine)
    1. More common and more severe in women
    2. Reduced Incidence if start dose slowly over 2 weeks
    3. Prophylaxis not recommended (e.g. Corticosteroids)
      1. Antinori (2001) AIDS 15:1579-81 [PubMed]
    4. Switching to a different drug class may be needed
    5. My progress to Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, Erythema Multiforme
      1. Severe rash is especially more common with Etravirine and especially in women

Images: Related links to external sites (from Bing)

Related Studies (from Trip Database) Open in New Window

Ontology: Non-Nucleoside Reverse Transcriptase Inhibitors [MoA] (C1373120)

Concepts Molecular Function (T044)
English Non-Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors [MoA]